A Phase 2 interventional study of RB-ADSC and Placebo in Alzheimer Disease, sponsored by Regeneration Biomedical, Inc.. Not yet recruiting. Open to participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Regeneration Biomedical, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this Phase 2 clinical trial is to learn if repeated dosing of RB-ADSC (an investigational autologous cell product obtained from participant's own adipose tissue) enhances the positive preliminary results seen in Phase 1 for the of treatment for mild to moderate Alzheimer's Disease in adults. The clinical trial will also continue to evaluate the safety of repeated dosing of RB-ADSC. This study will primarily evaluate the effects of repeated dosing of RB-ADSC on cognitive performance compared to placebo control. Participants will receive RB-ADSC every 2 months for a total of 6 doses. Participants randomized into the placebo control group will have the option to cross over to receive treatment after completion of the primary phase of the study.
This is a randomized, placebo-controlled, dose range finding for safety and efficacy, Phase 2a U.S. multicenter study of repeated administration of RB-ADSC in participants with mild to moderate Alzheimer's Disease AD. RB ADSC consists of stem cells obtained from the participant's own adipose tissue by lipoaspirate that have been cultured and expanded outside the body, enriched for Wnt-activated cells, and prepared for administration into the same participant. An Ommaya reservoir, which is an intraventricular catheter system, will be implanted under the scalp for intraventricular administration of RB-ADSC.
Approximately 115 adult participants are expected to be enrolled in this Phase 2a study. Participants will be randomized at a 4:1 ratio of RB-ADSC treatment to placebo. Participants randomized into the RB-ADSC treatment arm will be subsequently randomized with a 1:1 ratio to a treatment dose level: low-dose RB-ADSC (2.5 x 10\^6 cells), and high-dose RB-ADSC (5.0 x 10\^6 cells), for an overall randomization scheme of 2:2:1.
RB-ADSC will be delivered intracerebroventricularly every 2 months via the previously implanted Ommaya reservoir for a treatment duration of 10 months (inclusive of 10th month; up to 6 injections in total). Participants will be followed for 6 months after the last administration. The primary and secondary objectives will evaluate the efficacy based on cognitive, functional and CSF biomarker (Phospho-Tau, Total Tau, AB-42) assessments. Additionally, safety evaluations, volumetric MRI (Neuro Quant®) assessment, and diagnostic imaging comparison (Amyloid PET) will be performed.
After completing the Month 12 evaluation, participants in the placebo arm will be allowed to cross over to receive RB-ADSC. Participants in the cross-over will be randomized to a treatment dose level (low dose or high dose) at a 1:1 ratio. Cross-over participants will receive RB-ADSC doses every 2 months for a treatment duration of 10 months.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
This study's planned enrollment of 115 is above the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Regeneration Biomedical, Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive repeated doses of 2.5x10\^6 RB-ADSC infused in the previously implanted Ommaya reservoir
Biological: RB-ADSC
Participants will receive repeated doses of 5x10\^6 RB-ADSC infused in the previously implanted Ommaya reservoir
Biological: RB-ADSC
Participants will receive placebo comparator in the previously implanted Ommaya reservoir
Other: Placebo
RB-ADSC is an investigational an ex-vivo expanded autologous adipose-derived stem cell product
0.9% NaCl USP
Change from Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) Composite Score
iADRS will be used to assess whether RB-ADSC slows down the clinical decline associated with AD compared with placebo. iADRS evaluates cognition and daily function performance by combining items from the ADAS-Cog13 and the Alzheimer's disease cooperative study-instrumental activities of daily living scale (ADCS-iADL). The scale ranges from 0 to 144, where lower scores indicate worse performance and higher score indicates better performance.
Time frame: Baseline, Month 6 and Month 12
Change from Baseline in CSF Biomarkers
CSF Biomarkers will be measured with the ADmark® phospho-tau/total-tau/ Abeta-42 assay to determine the levels of Phosphorylated-Tau protein, Total-Tau protein, and Ab42 in the cerebrospinal fluid (CSF). The amyloid-tau index (ATI) will also be determined.
Time frame: Baseline, Month 6 and Month 12
Change from Baseline in MMSE
Cognitive function will be evaluated with the Mini Mental State Examination (MMSE). The range for the total MMSE score is 0 to 30, with lower scores indicating greater level of impairment.
Time frame: Baseline, Month 6 and Month 12
Change from Baseline in ADAS-cog13
Cognitive function will be assessed using the AD Assessment Scale - Cognitive (ADAS-cog13). The ADAS-Cog13 scale ranges from 0 to 85, with higher scores indicating greater disease severity.
Time frame: Baseline, Month 6 and Month 12
Change from Baseline in FAST
Functional abilities will be assessed using the Functional Assessment Staging Tool (FAST). The tool consists of seven stages, with higher scores indicating more severe impairment.
Time frame: Baseline, Month 6 and Month 12
Change from Baseline in ADCS-iADL
Functional ability will be assessed using the AD Cooperative Study-Activities of Daily Living Scale (ADCS-ADL). The iADL score ranges from 0 to 59, with lower scores indicating greater impairment.
Time frame: Baseline, Month 6 and Month 12
Change from Baseline in CDR-SB
Cognitive changes will be assessed with the Clinical Dementia Rating - Sum of Boxes (CDR-SB). Scores range from 0 to 18 with higher scores indicative of more impairment.
Time frame: Baseline, Month 6 and Month 12
Change from Baseline in Amyloid Positron Emission Tomography (Amyloid-PET)
Amyloid-PET will be used to quantitatively assess amyloid plaque deposition in the brain
Time frame: Baseline, Month 6 and Month 12
Change from Baseline in Volumetric MRI with Contrast
Volumetric MRI with contrast of the brain will be used to detect and monitor brain abnormalities.
Time frame: Baseline, Month 6 and Month 12
Change from Baseline in NeuroQuant MRI
NeuroQuant MRI will be used to measure volumes of brain structures.
Time frame: Baseline, Month 6 and Month 12
Safety of Repeated Dosing RB-ADSC
Safety will be determined by the number of treatment-related adverse events (AE) and serious adverse events (SAE) graded according to CTCAE v5.0 up to Month 16 compared to placebo control
Time frame: Up to Month 16
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Feb 2029, 28 months later.
Of 130 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 28 months is close to that.
Counting every sponsor, half of 257 studies reached it within 37 months; a quarter within 21 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Regeneration Biomedical, Inc.